Abstract
Background and aims
The prevalence of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) continue to increase at epidemic proportions [1] . Meanwhile, CVD is the leading cause of morbidity and mortality in people with diabetes. The UKPDS study reported that intensive blood glucose control resulted in a decrease in microvascular complications, while macrovascular complications were not significantly reduced and showed that the prevention of CVD through blood glucose control alone was insufficient [2] [3] [4] . As well, a more recent meta-analysis of the effect of intensive glucose control on CV outcomes including data from the UKPDS, ACCORD, ADVANCE and VADT trials showed a significant reduction in coronary heart disease (CHD) and CVD events, but no reduction in cardiovascular mortality or total mortality [5] . Aggressive control of hypertension and lowering low-density lipoprotein (LDL) cholesterol levels reduce the risk of cardiovascular events [6] . Therefore, the results from the Steno-2 study support the hypothesis that intensive integrated therapy in high-risk patients with T2DM has the potential to decrease the risk for both microvascular and macrovascular complications and mortality [7, 8] .
The typical patient with T2DM has multiple cardiovascular risk (CVR) factors, each of which should be treated in accordance with existing guidelines [6] . Initiation of intensive therapy soon after diabetes diagnosis was shown to reduce the risk of microvascular and macrovascular diseases [9] .
The aims of our study were: 1) to assess the control of the cardio-metabolic risk factors one year after initiating the clinical management in subjects with newly diagnosed T2DM; 2) to identify the baseline characteristics of the subjects with newly diagnosed T2DM associated with achievement of the goals for glycemia, blood pressure (BP) and LDL-cholesterol one year after diagnosis.
Material and methods
The baseline examination was carried out between 2006-2008 and included 968 individuals with T2DM registered at the Clinical Center of Diabetes Cluj-Napoca. The following inclusion criteria were used for the study: subjects with newly diagnosed T2DM (defined according to World Health Organization criteria [10]), aged ≥ 18 yrs. and availability of subject characteristics at baseline and a year after diagnosis. The final sample size was composed of 673 individuals with T2DM; 295 individuals were excluded (lost of follow-up, unavailability of all clinical data a year after diagnosis).
Diabetes care was based on a complete medical diagnosis and a comprehensive diabetes evaluation, followed by implementation of the clinical management strategy and subsequent evaluation of each patient's medical condition and treatment a year after diagnosis. The following data were evaluated: demographic characteristics (age, gender), medical history (CVD), anthropometric parameters (body mass index (BMI), waist circumference), glycemic control, lipid profile and blood pressure. The treatment of CVR factors was also evaluated. All clinical data were retrieved from the medical records and all patients included in the study were followed for one year. BMI <100 mg/dl) one year after diagnosis. P values < 0.05 were considered to be statistically significant.
Results
A total of 673 patients with newly diagnosed T2DM, 331 (49.2%) men and 342 (50.8%) women, were evaluated at diagnosis of T2DM and a year after. For the entire study group, the mean age at T2DM diagnosis was of 57.7 yrs. The anthropometric and biological characteristics of study subjects at diagnosis and one year after are given in The proportion of those reaching the optimal goals for major risk factors was 72.1% for HbA1c, 58.6% for BP and 40.3% for LDLcholesterol. As shown in Table 2 , all three goals were met by only 6.9% of the study subjects. A significantly higher percentage of men reached the lipid control for the total cholesterol (42.3% vs. 34.3%, p=0.02) and HDL-cholesterol (50.7% vs. 27.6%, p=0.001) a year after diagnosis, as shown in Table 3 .
Success rates for glycemic control (HbA1c <7%) appeared to be independent of demographic characteristics (age, sex), clinical parameters (BMI, BP) and CVD prevalence (Table 4) . Additionally, as HbA1c levels were lower initially, the HbA1c goal success rate increased a year after (7.1 ± 1.4% vs. 8.3 ± 1.5%, p<0.001). Baseline characteristics of the newly diagnosed T2DM subjects that independently influence achievement of treatment targets for HbA1c, BP and LDL-cholesterol one year after diagnosis, are given in Table 5 . Achieving the glycemic control is associated with a lower HbA1c value at diagnosis (OR: 0.66, 95%IC:0.54-0.81).
During the first year after diagnosis, the therapeutic structure changed significantly as shown in Table 6 .
We also assessed both at baseline and one year after diagnosis, the pharmacotherapy of BP control in people with hypertension, the pharmacotherapy of lipid control in people with dyslipidemia and also the use of aspirin (Table 7) . 
Discussions
The practical implementation of the standards of care for diabetes is not an easy task. The NHANES study (National Health and Examination Survey [2001] [2002] showed that among the people with T2DM 50.2% did not achieve the target for HbA1c, 64.66% did not reach the target for LDL-cholesterol, and 53.0% did not achieve the target for BP [12] . Only a multifactorial approach to the clinical management of diabetes, aiming not only at the glycemic control but also at the control of hypertension and dyslipidemia, may reduce the risk of CVD morbidity and mortality as shown by the Steno-2 study [7, 8] .
During the first year of carrying out the clinical management following the detection of T2DM in our study, a significant reduction in CVR factors was achieved and a good metabolic control was reached. In the Look AHEAD study, all three major goals (HbA1c, BP and LDLcholesterol) were met by only 10.1% overweight and obese individuals with T2DM, as compared with 6.9% in our study [13] . On the other hand, the glycemic, lipid and BP control were much improved in our study compared to the EPIDIAB data [14] .
The most significant results were recorded for the glycemic control. Treatment of T2DM has traditionally focused on glycemic control to decrease the risk of microvascular complications [3] .
The parameters which were initially identified as associated with achieving the major objectives of the clinical management one year after the detection were represented by: age, male gender, clinical parameters (HbA1c, the BMI, SBP, DBP), comorbidity (hypertension), pharmacotherapy (statins). These results show that many of the baseline characteristics of the people newly diagnosed with T2DM may influence the control of cardio-metabolic risk factors. Age, sex, degree of obesity and pharmacotherapy have been also associated in other studies also with the level of the risk factors control in diabetes [13] .
Targeting hyperglycemia alone does not reduce the excess risk in diabetes, highlighting the need for aggressive treatment of others risk factors [15] . Despite this, data from multiple sources suggest that those with diabetes do not experience optimal risk factor control compared to those without diabetes [16, 17] . In this study it was ascertained that the other cardiovascular risk factors (dyslipidemia, hypertension) benefited from less attention compared to glycemia, as suggested by the much lower percentage in reaching the established objectives. International treatment guidelines consider DM a high-risk condition for developing of CVD and treatment with cardioprotective agents such as statins, ACE inhibitors and aspirin are highly recommended for many diabetic patients [6, 18] .
The AUDIT study revealed a disparity between lipid screening and control in T2DM patients [19] . Although LDL-C is not usually elevated in T2DM relative to matched individuals without T2DM, it is one of the most important modifiable CVD risk factors [20] . LDL cholesterol-targeted statin therapy remains the preferred strategy [18] . However, statin therapy was recommended for a reduced number of people (44% of those with dyslipidemia) and only half of the people with CVD received statin therapy. Studies examining possible benefits of lipid lowering with fibrates in diabetes have given inconsistent results [6] . Nevertheless, 24.6% of the individuals in our study received fibrate treatment one year after the diagnosis, of whom 9.1% in the form of statin-fibrate combined therapy.
Significantly fewer women than men reached the current treatment goals for total cholesterol and HDL cholesterol. Gender differences in CVR factor treatment and control have been reported previously both in diabetic and non-diabetic patients [21, 22] .
In many studies, the proportion of individuals with diabetes who achieved hypertension control was low (about only one third of individuals with diabetes and hypertension) and also individuals with diabetes were less likely to achieve hypertension control than those without diabetes [23, 24] . The results of the present study may be explained in part by the fact that we used a lower threshold (< 130/80 mmHg) for hypertension control among individuals with diabetes, which is harder to achieve. In people with diabetes, inhibitors of the renin-angiotensin system may have unique advantages for initial or early theraphy of hypertension [18] . ACE inhibitors constituted the most recommended therapeutic agent in our study (59.6% at diagnosis and 44.1% a year after the diagnosis), whereas ARBs were recommended for a reduced number of people (4.2-4.6%).
There were no changes in the treatment with aspirin in people with CVD (44.1% vs. 44.6%), but the recommendation of aspirin for primary prevention therapy increased (34.2% vs. 24.4%). The studies have shown that the effects of aspirin therapy in people with diabetes are smaller than those for the general population, which has lead to a conservative approach about aspirin therapy for CVD prevention in people with diabetes [25] . The role of aspirin in primary prevention remains unproven [6] . However, antiplatelet therapy with aspirin is no longer recommended for people with diabetes who do not have clinical evidence of CVD [18] .
It is vital in T2DM patients to lower their CVD risk and prevent an epidemic of CVD morbidity and mortality and a parallel increase in healthcare costs [26] . Further efforts are needed to aggressively control CVD risk factors among individuals with newly diagnosed diabetes [16] . Targeting multiple markers of CVD risk hopefully offers the best chance of improving CVD outcomes [15] .
Conclusions
Implementing of the clinical management for the people with newly diagnosed T2DM resulted in improved glycemic control and cardiovascular risk factors. The practical implementation of standards of care for diabetes from the perspective of achieving short-term therapeutic goals proved difficult. The management of newly diagnosed people with T2DM focused specifically on achieving the glycemic target. The results of this study highlight the need for diabetes management to be directed towards the global cardiovascular risk. Our results also show that many of the baseline characteristics of the people newly diagnosed with T2DM may influence the control of cardio-metabolic risk factors one year after diagnosis.
